
Sign up to save your podcasts
Or


Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.
By Retina Synthesis4.5
88 ratings
Dr. Jamie Dananberg, Chief Medical Officer of Unity Biotechnology discusses their strategy of selectively targeting senescent retinal vascular endothelial cells for a more long lasting effect on altering the pathophysiology of diabetic eye disease.

18 Listeners

2,446 Listeners

112,758 Listeners

672 Listeners

56,463 Listeners

594 Listeners

4 Listeners

11 Listeners

51 Listeners

10 Listeners

18 Listeners

1 Listeners

0 Listeners

838 Listeners